Healio

FDA advisory committee backs combination drug for first-line therapy

The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted unanimously in favor of recommending approval of a new indication for irbesartan-hydrochlorothiazide as initial treatment of ...
FiercePharma

FDA advisors spurn GSK's Blenrep comeback dreams on safety, trial concerns

The FDA’s Oncologic Drugs Advisory Committee voted against GSK's Blenrep in both of its proposed combinations. (U.S. Food and Drug Administration) On a quest to bring its multiple myeloma ...
Seeking Alpha

Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

- Columvi is the first bispecific antibody to show a statistically significant and clinically meaningful 41% survival benefit in R/R DLBCL in the Phase III STARGLO study - - There is an urgent need ...
Yahoo Finance

Auddia Announces Leadership Changes and Special Committee to Evaluate Business Combination and Restructuring as AI Native Holding Company

BOULDER, Colo., July 09, 2025 (GLOBE NEWSWIRE) -- Auddia Inc. (NASDAQ: AUUD) (NASDAQ: AUUDW) ("Auddia" or the "Company"), today announced that Jeff Thramann has succeeded Michael Lawless as CEO of ...
Business Wire

FDA Advisory Committee Votes in Favor of the Clinical Benefit of Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma

“Today’s committee decision to recognize the potential of this Polivy combination as a first-line treatment option is important since four in 10 people with diffuse large B-cell lymphoma relapse or do ...
National Institute for Health and Care Excellence

Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma

The evaluation committee considered evidence submitted by Takeda and a review of this submission by the external assessment group (EAG). See the committee papers for full details of the evidence.
Mena FN

Auddia Announces Leadership Changes And Special Committee To Evaluate Business Combination And Restructuring As AI Native Holding Company

(MENAFN- GlobeNewsWire - Nasdaq) Jeff Thramann, Executive Chairman of Auddia, has succeeded Michael Lawless, who is retiring, as CEO to oversee restructuring New independent board members with ...